People are lining up—and in some cases paying five figures a year—to inject substances the FDA hasn’t signed off on. In the New Yorker, physician-writer Dhruv Khullar digs into the booming world of peptides: short amino-acid chains sold as everything from injury repair tools to longevity hacks. The piece explains that peptides have legitimate medical uses (think insulin or GLP-1 drugs) but are now being embraced by biohackers, athletes, concierge doctors, and the like (podcasters Joe Rogan and Andrew Huberman swear by them) for a wide range of uses despite a lack of rigorous medical evidence. Khullar traces how legitimate lab discoveries have morphed into a gray-market free-for-all, one that is lightly regulated.
Many users are effectively experimenting on themselves, sourcing compounds from compounding pharmacies or gray-market suppliers. The problem is that while the science may be promising, it’s also incomplete. Scientists quoted in the story stress that anecdotal success stories don’t equal evidence—and that unknown risks (including contamination, immune reactions, or even cancer-related effects) remain a serious concern. At the same time, the piece doesn’t dismiss the movement outright. It notes a long American tradition of “medical freedom” and self-experimentation, and explains how advocates see peptides as the next frontier in personalized medicine—potentially ahead of slow-moving regulatory systems. In short, peptides currently sit in a gray area where legit science meets DIY experimentation. Read the deeply reported story in full.
